Cellosaurus cell line SU-DIPG-VI (CVCL_IT40)

• Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062; PubMed=34732238).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=34732238).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Glu198Ter (c.592G>T); ClinVar=VCV000634704; Zygosity=Unspecified (PubMed=34732238).
  

PubMed=24777482; DOI=10.1007/s00401-014-1272-4
Caretti V., Sewing A.C.P., Lagerweij T., Schellen P., Bugiani M., Jansen M.H.A., van Vuurden D.G., Navis A.C., Horsman I., Vandertop W.P., Noske D.P., Wesseling P., Kaspers G.J.L., Nazarian J., Vogel H., Hulleman E., Monje M., Wurdinger T.
Human pontine glioma cells can induce murine tumors.
Acta Neuropathol. 127:897-909(2014)

PubMed=25366336; DOI=10.1093/neuonc/nou303
Green A.L., Ramkissoon S.H., McCauley D., Jones K., Perry J.A., Hsu J.H.-R., Ramkissoon L.A., Maire C.L., Hubbell-Engler B., Knoff D.S., Shacham S., Ligon K.L., Kung A.L.-J.
Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Neuro-oncol. 17:697-707(2015)

PubMed=25939062; DOI=10.1038/nm.3855
Grasso C.S., Tang Y.-J., Truffaux N., Berlow N.E., Liu L.-N., Debily M.-A., Quist M.J., Davis L.E., Huang E.C., Woo P.J., Ponnuswami A., Chen S., Johung T.B., Sun W.-C., Kogiso M., Du Y.-C., Qi L., Huang Y.-L., Hutt-Cabezas M., Warren K.E., Le Dret L., Meltzer P.S., Mao H., Quezado M., van Vuurden D.G., Abraham J., Fouladi M., Svalina M.N., Wang N., Hawkins C., Nazarian J., Alonso M.M., Raabe E.H., Hulleman E., Spellman P.T., Li X.-N., Keller C., Pal R., Grill J., Monje M.
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Nat. Med. 21:555-559(2015)

PubMed=28823557; DOI=10.1016/j.cell.2017.07.016
Qin E.Y., Cooper D.D., Abbott K.L., Lennon J., Nagaraja S., Mackay A., Jones C., Vogel H., Jackson P.K., Monje M.
Neural precursor-derived pleiotrophin mediates subventricular zone invasion by glioma.
Cell 170:845-859.e19(2017)

PubMed=33319914; DOI=10.1093/gigascience/giaa136
Sanders L.M., Cheney A., Seninge L., van den Bout A., Chen M., Beale H.C., Kephart E.T., Pfeil J., Learned K., Lyle A.G., Bjork I., Haussler D., Salama S.R., Vaske O.M.
Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma.
GigaScience 9:giaa136.1-giaa136.14(2020)

PubMed=34215733; DOI=10.1038/s41467-021-24168-8
He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N., Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J., Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J., Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P., Boop F., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M., Freeman B.B. III, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z., Wu G., Chiang J., Tinkle C.L., Shelat A.A., Baker S.J.
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma.
Nat. Commun. 12:4089.1-4089.17(2021)

PubMed=34732238; DOI=10.1186/s40478-021-01270-y
Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H., Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Acta Neuropathol. Commun. 9:178.1-178.12(2021)